Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal-happy Roche acquires Trophos

This article was originally published in Scrip

Executive Summary

In yet another deal, Roche is acquiring rare disease drug developer Trophos at a price of €120m upfront, and a further €350m in potential milestone payments.

You may also be interested in...



Roche Sticking With SMA Despite Terminating Olesoxime

Problems over formulation and the arrival of effective treatment options in spinal muscular atrophy, headed by Biogen's antisense oligonucleotide drug Spinraza, have led to the plug being pulled on olesoxime - but the Swiss major has a back-up candidate.

Horama Joins Race To Develop Gene Therapies For Eye Diseases

Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.

In Vivo’s Deals Of The Year 2020: Cast Your Vote!

It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel